Pediatric Community-Acquired Pneumonia Treatment
Introduction to Treatment
- The American Thoracic Society and the Infectious Diseases Society of America recommend amoxicillin as the first-line antibiotic treatment for pediatric community-acquired pneumonia in children under 5 years, while macrolide antibiotics are recommended as first-line therapy for children 5 years and older 1, 2
- The British Thoracic Society recommends first-line therapy with amoxicillin combined with a macrolide for patients with pneumonia, covering both typical and atypical pathogens 1, 3
First-Line Treatment
- Oral amoxicillin is recommended as first-line treatment for children under 5 years with a dosage of 45-90 mg/kg/day divided in 2-3 doses 1
- Macrolide antibiotics, such as clarithromycin or azithromycin, are recommended as first-line treatment for children 5 years and older 1
- The duration of amoxicillin treatment is 5-7 days for mild-moderate pneumonia 2
Alternative Options
- For patients with non-type 1 hypersensitivity to penicillin, cefuroxime, cefaclor, or other cephalosporins are recommended as alternative options 1
- For patients with type 1 hypersensitivity to penicillin, macrolides such as clarithromycin or azithromycin are recommended as alternative options 1
- Alternative options for penicillin-allergic patients include macrolide monotherapy (erythromycin, clarithromycin, or azithromycin) 3
Oxygen Therapy and Intravenous Antibiotics
- Oxygen therapy is recommended if oxygen saturation is ≤92% 1
- Intravenous antibiotics are recommended when the child is unable to absorb oral antibiotics, has severe signs and symptoms, or has a high risk of treatment failure 1
- Co-amoxiclav, cefuroxime, or cefotaxime are recommended as intravenous antibiotic options 1
Treatment Duration and Follow-Up
- The treatment duration for mild-moderate pneumonia is 5-7 days 2
- The treatment duration for pneumonia with effusion is 2-4 weeks, depending on drainage adequacy and clinical response 2
- A minimum of 5 days of antibiotic therapy is recommended, with the patient being afebrile for 48-72 hours before discontinuation 3, 4
- For severe cases with undefined etiology, 10 days of treatment is recommended 3
- Follow-up is recommended within 48-72 hours to assess response to treatment, and clinical review should be arranged for all patients at around 6 weeks 1, 3
Management of Complications
- Small effusions can be managed with antibiotics alone without drainage 2
- Moderate-large effusions with respiratory distress require drainage, which can be done using a chest tube with or without fibrinolytics or VATS 2
- Patients with oxygen saturation <92% or signs of respiratory distress require inpatient management, as recommended by the British Thoracic Society 1
Prevention
- Influenza vaccination is recommended for high-risk groups, including those with chronic lung/heart/renal/liver disease, diabetes mellitus, immunosuppression, and adults >65 years 3
- Pneumococcal vaccination is recommended for those aged ≥2 years at high risk for pneumococcal infection 3
Special Considerations
- For patients at risk of Pseudomonas, antipneumococcal, antipseudomonal β-lactam plus either ciprofloxacin/levofloxacin or the β-lactam plus an aminoglycoside and azithromycin should be used 4
- For community-acquired MRSA, vancomycin or linezolid should be added to the treatment regimen 4
- For severe pneumonia, two antibiotics from different classes (avoiding two β-lactams) plus MRSA coverage with vancomycin or linezolid should be used 5
- Risk factors for multidrug-resistant (MDR) pathogens should be assessed, including prior intravenous antibiotic use within 90 days and hospitalization in a unit with high rates of methicillin-resistant S. aureus 3
Common Pitfalls
- Delayed reassessment of non-responding patients can lead to poor outcomes, and reassessment should be done within 48 hours 1, 3
- Overuse of fluoroquinolones is not recommended due to concerns about resistance development and side effects 3
- Unnecessary chest physiotherapy should not be performed 1
- Inappropriate fluid management can lead to complications, and fluids should be given at 80% of basal levels with electrolyte monitoring if needed 1